Effects of the anti-TNF-antibody infliximab on markers of bone turnover in patients with rheumatoid arthritis.

被引：0
|
作者：
Mueller, TJ
Hermann, J
Fahrleitner, A
Yazdani-Biuki, B
Dimai, HP
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2001年 / 44卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1076
引用
收藏
页码：S232 / S232
页数：1
相关论文
共 50 条
  • [31] EFFECTS OF ANTI-TNF THERAPY ON MARKERS OF BONE HOMEOSTASIS IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Horvth, A.
    Pusztai, A.
    Gulyas, K.
    Vancsa, A.
    Vegh, E.
    Bodnar, N.
    Csomor, P.
    Petho, Z.
    Juhsaz, B.
    Szentpetery, A.
    Szamosi, S.
    Bhattoa, H.
    Szanto, S.
    Szucs, G.
    Nagy, Z.
    Szekanecz, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : A37 - A37
  • [32] Infliximab (anti-TNF-alpha antibody) could improve insulin resistance in rheumatoid arthritis patients.
    Dobashi, H
    Kittaka, K
    Tokuda, M
    Oonishi, I
    Inoo, M
    Ishida, T
    Kurata, N
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S377 - S377
  • [33] Infliximab sustains employability in patients with early rheumatoid arthritis.
    St Clair, EW
    Burch, F
    Han, CL
    Bala, M
    Baker, D
    Han, J
    Smolen, J
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S400 - S400
  • [34] Safety of infliximab in daily practice in patients with rheumatoid arthritis.
    Neven, N
    Vis, M
    Voskuyl, AE
    Wolbink, GJ
    Nurmohamed, MT
    Dijkmans, BAC
    Lems, WF
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S331 - S331
  • [35] Anti-Carbamylated Protein Antibody In Japanese Patients With Rheumatoid Arthritis.
    Shiozawa, Shunichi
    Trouw, Leendert A.
    Shiozawa, Kazuko
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S980 - S981
  • [36] A single infusion of the tumor necrosis factor-alpha antibody infliximab suppresses bone resorption in patients with rheumatoid arthritis.
    Dimai, HP
    Mueller, T
    Fahrleitner, A
    Hermann, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S274 - S275
  • [37] Effects of TNF blockade by infliximab on inflammasome regulators in rheumatoid arthritis patients
    Mathews, R.
    Churchman, S.
    Church, L.
    Coulthard, L.
    Bryer, D.
    Nizam, S.
    Saleem, B.
    Cook, G. P.
    Emery, P.
    McDermott, M. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 : A25 - A26
  • [38] Pharmocogenomic analysis of the effects of infliximab and the appearance of HACA (a neutralixing antibody against infliximab) in clinical treatment of rheumatoid arthritis.
    Matsubara, Tsukasa
    Funahashi, Keiko
    Ji, Guijin
    Baba, Masanori
    Sato, Hidenori
    Saji, Hiromi
    Emi, Mitsuru
    Ichien, Go
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S329 - S330
  • [39] Effects of infliximab on bone turnover markers in patients with rheumatoid arthritis: Improvement of bone remodeling balance and differential effects on cathepsin K and matrix-metalloproteases mediated bone resorption
    Thomas, T
    le Henanff, A
    Debiais, F
    Daragon, A
    Roux, C
    Sany, J
    Wendling, D
    Zarnitsky, C
    Ravaux, P
    Garnero, P
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S143 - S143
  • [40] Long-term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis.
    Rau, R
    Sander, O
    den Broeder, A
    van Riel, PLCM
    van der Putte, L
    Krüger, K
    Schattenkircher, M
    Fenner, H
    Lassmann, A
    Kupper, H
    Kempeni, J
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S55 - S55
12345